INS and metabolic dysfunction-associated steatohepatitis: In the T2DM-NASH-Cele group, we observed that celecoxib weakened central lipolysis indicated by increased EAW/BW and decreased liver weight index, compared with the T2DM-NASH group.Besides, we observed that celecoxib ameliorated insulin resistence, including reduced serum insulin level, HOMA-IR, glucose AUC and increased insulin sensitivity in the T2DM-NASH-Cele group.